http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2815224-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37629fa7c35016ee77d00364d195f483 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2458-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-24035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-24003 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-24023 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-24024 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6857 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6491 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2015-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1d2d8684a46fd60cc872ae78b808489 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b4fd399f13ef8ce9f0adba1ef8df742 |
| publicationDate | 2021-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2815224-T3 |
| titleOfInvention | A method to quantify therapeutic antibodies |
| abstract | A method for quantifying a therapeutic antibody in a sample from a human individual, comprising the steps of: a) adding to a test sample that may contain therapeutic antibodies to be quantitated a known amount of two or more labeled forms of said therapeutic antibodies, whereby a preproteolysis sample is provided, b) subjecting the preproteolysis sample to enzymatic proteolysis, to provide a proteolysis sample comprising (i) labeled proteolysis peptides derived from the labeled therapeutic antibodies and (ii) proteolysis peptides derived from the therapeutic antibody contained in the test sample, c) determining by mass spectrometric analysis the relationship between (i) one or more selected proteolysis labeled peptides and (ii) one or more corresponding proteolysis peptides derived from said therapeutic antibody, d) calculate, from the ratio determined in step c), the amount of said antibody therapeutic in the test sample; wherein the test sample is a human plasma sample or a human serum sample, and the two or more antibodies are selected from a group consisting of: Infliximab, Etanercept, Adalimumab, Certolizumab, Golimumab, Trastuzumab, Rituximab, and Bevacizumab . |
| priorityDate | 2015-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 165.